boehringer-ingelheim-limited

Media

RELY-ABLE® Study Demonstrates Benefits of Pradaxa® (Dabigatran Etexilate) Are Maintained for over Four Years

Media

Phase III Results: Once-daily tiotropium Significantly Increases Time to First Severe Exacerbation and Reduces the Risk of Exacerbations in Asthma Patients Still Symptomatic Despite ICS/LABA Treatment